This approach was largely affirmed by others during the public comment period. Components of the ICH score and 1 straight- forward method of calculating ICH hematoma volume can be found in work by Hemphill et al22 and Kothari et al.25 The performance measure for reversal of coagulopathy follows from the 2015 AHA/ASA ICH guidelines Class I rec- ommendation for discontinuation of vitamin K antagonists in patients with acute ICH with an elevated international nor- malized ratio and administration of therapy to replace vitamin K dependent clotting factors. The 2015 ICH guidelines do not provide a Class I recommendation as to whether to use prothrombin complex concentrates or fresh-frozen plasma and do not specify a time frame in which therapy must be administered. The optimal therapy and timing for vitamin K antagonist reversal in acute ICH have received notable atten- tion in the time since the literature review for the 2015 ICH Although a recent clinical trial sug- gested superiority of prothrombin complex concentrates over the writing group felt that the level of existing recommendations and available data best supported that, to meet this performance measure, the administration of either was acceptable. TJC has an existing Comprehensive Stroke Center metric about this topic. However, the writing group felt that the absence of any time frame for administra- tion did not appropriately reflect quality because treatment with prothrombin complex concentrates or fresh-frozen plasma at a time point outside the hyperacute period was not the intended approach and meeting the metric by treat- ing many hours after ictus was not reflective of quality care. 